Bank of America just raised its EUR/USD forecast
HONG KONG - Hutchmed (China) Limited (Nasdaq/AIM: HCM; HKEX: 13), a biopharmaceutical company, has announced an upcoming Extraordinary General Meeting (EGM) to discuss the proposed sale of its 45% stake in Shanghai Hutchison Pharmaceuticals Limited, a move first publicized on January 1, 2025. The EGM is set to take place electronically and in person at the Cheung Kong Center in Hong Kong on Monday, March 31, 2025, at 3:00 pm local time.
Shareholders are expected to deliberate on the divestiture, which has been a subject of discussion since the initial announcement and a subsequent update on March 2, 2025. The company has encouraged its shareholders to thoroughly review the EGM Materials, which include the Circular and the Form of Proxy. These documents will be available on the Hutchmed website starting March 14, 2025, and will be sent in printed form to shareholders who prefer physical copies.
Hutchmed specializes in the development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company, which has brought three medicines to market in China and has received approval for its first drug in the US, Europe, and Japan, aims to extend its global reach in healthcare.
The EGM will allow shareholders to access the meeting online, providing an opportunity for broader participation. The outcome of the meeting will determine the approval of the strategic disposal of the equity interest in Shanghai Hutchison Pharmaceuticals Limited, which is part of Hutchmed’s ongoing business operations and strategy.
This information is based on a press release statement issued by Hutchmed (China) Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.